Showing results (1251-1260 of 1,611) with videos related to

Sort By:
Pageof 162
JAMA Oncology|September 25, 2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical TrialFatima Cardoso, William Jacot, Sherko Kuemmel, et al.
JAMA Oncology|September 25, 2025
Low-Dose Aspirin for Individualized Cancer Prevention in Older Adults: A Secondary Analysis of the ASPREE Randomized Clinical TrialLe Thi Phuong Thao, Tri-Long Nguyen, Jasmine Singh, et al.
JAMA Oncology|December 23, 2020
Maternally Orphaned Children and Intergenerational Concerns Associated With Breast Cancer Deaths Among Women in Sub-Saharan AfricaMoses Galukande, Joachim Schüz, Benjamin O Anderson, et al.
JAMA Oncology|December 30, 2020
Trends in Industry Payments to Medical Oncologists in the United States Since the Inception of the Open Payments Program, 2014 to 2019Elizabeth S Tarras, Deborah C Marshall, Kenneth Rosenzweig, et al.
JAMA Oncology|January 3, 2020
Life Expectancy of Adult Survivors of Childhood Cancer Over 3 DecadesJennifer M Yeh, Zachary J Ward, Aeysha Chaudhry, et al.
JAMA Oncology|January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical TrialAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
JAMA Oncology|December 27, 2019
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJianchun Duan, Longgang Cui, Xiaochen Zhao, et al.
JAMA Oncology|December 27, 2019
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung CancerGanessan Kichenadasse, John O Miners, Arduino A Mangoni, et al.
JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.
JAMA Oncology|December 13, 2019
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A ReviewFrancesco Maura, Niccolò Bolli, Even H Rustad, et al.
Pageof 162